On May 15, 2025, Biodexa Pharmaceuticals Plc announced a reduction in the exercise price of various Series E, H, J, and K Warrants to $0.31 each, resulting in the exercise of 200,433 Warrants and expected gross proceeds of approximately $62,000 by May 19, 2025.